Abattis Bioceuticals Corp  

(Public, CNSX:ATT)   Watch this stock  
Find more results for cnsx:flu
+0.0150 (37.50%)
Oct 2 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.05 - 0.06
52 week 0.01 - 0.31
Open 0.05
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS     -
Shares 85.10M
Beta     -
Inst. own     -


355 Burrard St Suite 1000
+1-604-5386650 (Phone)
+1-604-8881519 (Fax)

Website links


Abattis Bioceuticals Corp. is a Canada-based specialty biotechnology company. The Company, through its wholly owned subsidiaries, is involved in cultivating, licensing and marketing ingredients and formulas for use in the Medical Marijuana, BioPharma, Neutraceutical, Cosmetic and Animal Nutrition markets to medicinal markets in North America. The Company also has a pipeline of products and intellectual property for the botanical drug market. The Company has a pipeline of products in the functional foods and supplements business. It focuses on refining and marketing a portfolio of nutraceutical formulations of botanical agents for various strains of human influenza and other viral diseases. It also provides products for the treatment of migraine headache and Hemp, a non-psychoactive product derived from plants of the Cannabis genus.

Officers and directors

William Fleming Chief Executive Officer
Rene David Chief Financial Officer, Chief Operating Officer
Hugh Oswald IR Contact Officer
Barry Comis Director
Jim Irving Director
Brazos Minshew Director
Guy P. Dancosse QC Independent Director
Terence Fealey Ph.D. Independent Director
Age: 66